Welcome to our dedicated page for Ir-Med SEC filings (Ticker: IRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IR-MED Inc. (OTCQB: IRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other periodic filings. These documents offer detailed insight into IR-MED’s financial condition, capital-raising activities, executive arrangements and risk disclosures as it develops noninvasive, AI-driven spectrographic and infrared spectroscopy platforms for pressure injury and diabetic foot ulcer assessment.
For this medical technology company, SEC filings are a primary source for understanding funding transactions, such as private placements of common stock and warrants, and participation by company insiders. For example, Form 8-K filings describe securities purchase agreements, the number of shares and warrants issued, and the consideration received. They also outline the exemptions from registration relied upon for these offerings.
Filings further document changes to executive employment terms and the impact of financial challenges. In a recent Form 8-K, IR-MED reported amendments to employment agreements with senior officers, moving from fixed salaries to hourly compensation in light of its financial situation. The same filing notes that financial difficulties delayed the company’s Quarterly Report on Form 10-Q for a specified period and that IR-MED is evaluating alternatives to address its liquidity needs, while intending to resume timely periodic reporting when feasible.
On Stock Titan, IRME filings are updated in near real time as they appear on EDGAR, and AI-powered summaries can help explain the key points in complex documents. Investors can review 8-Ks for material events, as well as annual and quarterly reports when available, to examine risk factors, management’s discussion of operations, and details relevant to IR-MED’s pressure injury and diabetic foot ulcer programs.
Users interested in insider participation, financing structure, and the company’s stated risks and uncertainties can use this page to navigate directly to the most relevant IR-MED filings and AI-generated highlights.
IR-Med, Inc. entered a Securities Purchase Agreement for a private placement of 14,070,644 common shares at $0.0031 per share and warrants to buy up to 7,035,322 additional shares at $0.03 per share, raising gross proceeds of $43,619 when the deal closed.
Several directors, including Oded Bashan and other board members, participated by purchasing most of the shares and warrants on the same terms. The five-year warrants are exercisable immediately. The company also disclosed that Chief Executive Officer Ran Ziskind resigned effective February 3, 2026, citing disagreements with the company’s strategic direction, management approach, and certain employment matters.
IR-Med, Inc. reported that it has amended employment terms for its CEO and CFO and is facing significant financial pressures that have delayed required SEC reporting. Effective December 1, 2025, CEO Ran Ziskind moved from a fixed salary to an hourly rate of NIS 37 per hour, which the board may raise up to NIS 300 per hour if a significant funding round is secured. CFO Sharon Levkoviz also shifted from a reduced fixed salary to an hourly rate of NIS 185 per hour.
The company disclosed that due to current financial difficulties it did not file its Q3 2025 Form 10-Q by the deadline. IR-Med is evaluating alternatives to address its liquidity needs and intends to resume timely SEC filings once its financial challenges are resolved, but it gives no assurance on the timing or outcome of these efforts.
IR-Med, Inc. reported a private financing in which it entered into a Securities Purchase Agreement with investors on September 14, 2025. The company sold 1,562,500 shares of common stock at $0.016 per share and issued Warrants to purchase up to 781,250 additional shares at an exercise price of $0.05 per share, generating aggregate gross proceeds of $25,000. The transaction closed on September 16, 2025.
The company’s Chief Executive Officer, Ran Ziskind, participated by purchasing 937,500 shares and 468,750 Warrants for a total of $15,000. The Warrants are exercisable immediately and have a five-year term. The securities were issued in a private placement exempt from registration under Section 4(a)(2), Rule 506(b) of Regulation D, and Regulation S, and may not be sold in the United States without registration or a valid exemption.